Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Prostate cancer is the most common cancer among the geriatric male population. It is a major health concern, especially in developed countries with a greater proportion of elderly men being affected by it. According to European Association of Urology, 2016, the incidence is highest in Northern and Western Europe (> 200 per 100,000 men with age group > 70 years of age), while rates in Eastern and Southern Europe have showed a continuous increase. Thus, the introduction of innovative drugs for patients with prostate cancer is required to meet the unmet needs with satisfactory results. Currently, metastatic castration-resistant prostate cancer (CRPC) is usually treated with chemotherapy (docetaxel, and cabazitaxel) or secondary hormonal therapeutic agents such as abiraterone or Triptorelin. Immunotherapy with Sipuleucel-T is prescribed in treating asymptomatic or minimally metastatic CRPC without visceral metastasis.
Market Dynamics
The market is gaining significant traction due to continuous investment by research organizations and universities for the development of therapeutic products for the treatment of such tumors. Novel therapies are expected to be predominately approved in castration-resistant patients, and to compete with better-established treatments, such as Zytiga, Xtandi and generic docetaxel, or to act as adjuvants to established therapies. For instance, there is a strong pipeline of products such as Metformin (Mansoura University), Avelumab (Duke University Medical Center), LY2452473 (Dana-Farber Cancer Institute), which are in their phase 2 studies and are projected to enter the market in the near future. However, high cost and side effects associated with drugs can restraint the market growth.
Key features of the study:
This report provides in-depth analysis of the prostate cancer therapeutics market and its application, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2017 – 2025, considering 2016 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global prostate cancer therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
Key companies covered as a part of this study include Johnson & Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Inc, Endo Pharmaceuticals, AbbVie, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion and marketing tactics.
The global prostate cancer therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for prostate cancer therapeutics market, research and consulting firms, new entrants and financial analysts
Various strategy matrices used in analyzing the prostate cancer therapeutics market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
Global Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Global Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Prostate Cancer Therapeutics Market, By Geography:
North America
U.S.
U.S. Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
U.S. Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Canada
Canada Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Canada Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
U.K.
U.K. Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
U.K. Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Germany
Germany Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Germany Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Italy
Italy Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Italy Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
France
France Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
France Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Spain
Spain Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Spain Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Russia
Russia Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Russia Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Europe
Rest of Europe Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Rest of Europe Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia-Pacific
China
China Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
India
India Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
India Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Japan
Japan Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Japan Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
ASEAN
ASEAN Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
ASEAN Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Australia
Australia Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Australia Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
South Korea
South Korea Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
South Korea Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Asia Pacific
Rest of Asia Pacific Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Rest of Asia Pacific Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
Brazil
Brazil Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Brazil Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Mexico
Mexico Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Mexico Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Latin America
Rest of Latin America Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Rest of Latin America Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
GCC
GCC Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
GCC Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Israel
Israel Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Israel Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Middle East
Rest of Middle East Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Rest of Middle East Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
North Africa
North Africa Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
North Africa Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Central Africa
Central Africa Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Central Africa Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
South Africa
South Africa Prostate Cancer Therapeutics Market, By Drug Type:
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
Abiraterone Acetate (Zytiga)
Degarelix Acetate (Firmagon/Gonax)
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Goserelin Acetate (Zoladex)
Leuprorelin acetate (Prostap or Lutrate)
Triptorelin (Trelstar)
Others
Anti-Androgens
Enzalutamide (Xtandi)
Nilutamide (Nilandron)
Others
Immunotherapy
Sipuleucel-T (Provenge)
Targeted Therapy
Radium 223 Dichloride (Xofigo)
Chemotherapy
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
South Africa Prostate Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Johnson & Johnson
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Future Plans
Astellas Pharma Inc.
AstraZeneca Plc
Sanofi
Bayer AG
Pfizer, Inc.
Dendreon Corporation (Sanpower Group Co. Ltd.)
Ipsen Group
Tolmar Inc.
Endo International plc
AbbVie, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
